Table 3.
Risk of incident malignancies occurring after “start date” – comparison of the hydroxychloroquine/chloroquine exposed and unexposed periods
| Exposed time | Unexposed time | Crude sHR* | p-value | Adjusted sHR* | p-value | |
|---|---|---|---|---|---|---|
| Time at risk (year) | Time at risk (year) | |||||
| Incidence rate (per 100 PY) | Incidence rate (per 100 PY) | |||||
| Non-skin cancers | 36,320 | 127,188 | 0.97 (0.85–1.11) | 0.67 | 1.00 (0.88–1.15)a | 0.96 |
| 0.76 | 0.83 | |||||
| Hematological malignancies | 36,718 | 129,192 | 0.99 (0.70–1.39) | 0.95 | 0.89 (0.62–1.29)b | 0.55 |
| 0.11 | 0.12 | |||||
| Skin cancers | 36,247 | 127,342 | 1.02 (0.87–1.20) | 0.79 | 0.94 (0.80–1.12)b | 0.50 |
| 0.55 | 0.55 |
Notes:
*
Exposed compared to unexposed.
a
Adjusted on age, sex, underlying condition, smoking status, past history of cancer, deprivation index, and number of NSAIDs, metformin, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions.
b
Adjusted on age, sex, underlying condition, smoking status, past history of cancer, deprivation index, and number of NSAIDs, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions.
Abbreviations: NSAIDs, nonsteroidal antiinflammatory drugs; PY, person-years; sHR, sub-distribution hazard ratios.